Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes.
about
Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass.Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopeniaImmune mechanisms in heparin-induced thrombocytopenia: no evidence for immunoglobulin M anti-idiotype antibodies.Lepirudin in the management of patients with heparin-induced thrombocytopenia.Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia.Fondaparinux: does it cause HIT? Can it treat HIT?Utility of ELISA optical density values and clinical scores for the diagnosis of and thrombosis prediction in heparin-induced thrombocytopenia.IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics.The utility of pre-test clinical scoring for clinical diagnosis of heparin-induced thrombocytopenia in cardiac surgery patients of a tertiary care centre in north India.Assessment of the 4Ts pretest clinical scoring system as a predictor of heparin-induced thrombocytopenia.Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients.Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism: findings from the RIETE Registry.HIT paradigms and paradoxes.Rapid and simple IgG specific test for the exclusion of heparin induced thrombocytopenia (HIT).Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series.Anti-PF4/heparin antibodies are associated with arteriovenous fistula thrombosis in non-diabetic hemodialysis patients.Incidence of isolated heparin-induced thrombocytopenia and risk of thrombosis by IgG-specific anti-PF4/heparin ELISA.Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity.Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Argatroban therapy for heparin-induced thrombocytopenia during pregnancy in a woman with hereditary antithrombin deficiency.Evaluation of two new automated chemiluminescent assays (HemosIL® AcuStar HIT-IgG and HemosIL® AcuStar HIT-Ab) for the detection of heparin-induced antibodies in the diagnosis of heparin-induced thrombocytopenia.The Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice.Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia.Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis.Heparin-induced multiple electrode aggregometry is a promising and useful functional tool for heparin-induced thrombocytopenia diagnosis: confirmation in a prospective study.Contributions of biological tests and the 4 Ts score in the diagnosis of heparin induced thrombocytopenia.Critical role for mouse marginal zone B cells in PF4/heparin antibody production.FcγRIIa proteolysis as a diagnostic biomarker for heparin-induced thrombocytopenia.Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.The clinical significance and risk factors of anti-platelet factor 4/heparin antibody on maintenance hemodialysis patients: a two-year prospective follow-up.Impact of an immunoglobulin G-specific enzyme-linked immunosorbent assay on the management of heparin-induced thrombocytopenia.Prospective observational evaluation of the particle immunofiltration anti-platelet factor 4 rapid assay in MICU patients with thrombocytopenia.High sensitivity and specificity of a new functional flow cytometry assay for clinically significant heparin-induced thrombocytopenia antibodies.Alternative diagnosis to heparin-induced thrombocytopenia in two critically ill patients despite a positive PF4/heparin-antibody testB-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia.Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study.Prospective evaluation of automatized PF4/heparin immunoassays HemosIL HIT-ab (PF4-H) for the diagnosis of heparin-induced thrombocytopenia.Comparison of three different immunoassays in the diagnosis of heparin-induced thrombocytopenia.Outcome of patients with positive heparin-platelet factor-4 antibodies: A retrospective multi-institutional observational study.Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system
P2860
Q33377839-05A8AA3A-9D16-4C2E-9995-646434CDF070Q33381447-46596056-5D65-4ED4-93E6-9EEE32E7FB39Q33384840-FBD5B630-6937-4D3B-91CD-1781C62CC3E4Q33385972-E11461E9-F494-4EE8-BB18-6F223DF3E1F1Q33389839-EAE3A9D3-9DA6-4095-9C54-49049060F595Q33392864-985A2DE2-A62B-4C84-B6B5-602E43442A25Q33393683-78C0F7B0-FA53-4E14-9AD2-A28C699F2A0FQ33393788-91238B1B-6A3E-44D9-AC90-66A1B21D7C07Q33393837-17B01AFD-BE3A-4787-AFAA-5CF127185DF1Q33393894-4E08B83D-12A8-495B-B1FC-1B73ED7698E5Q33395517-76BFD8D9-0606-4511-AE62-7CF6D8465318Q33395797-84680F09-21C9-47BD-B634-52979B23B052Q33396313-9B4297B9-B701-49FD-AA96-4A85236D3267Q33396893-5E4FBF28-FEA0-4C85-9E68-4A76A7C97FD9Q33396967-953C7C1D-8BF1-4095-854A-EA54AC637560Q33397873-9A02889E-1E54-4782-B501-A76BA039ADA2Q33398047-38845ECF-73C1-4321-B3AD-4C45A548AD04Q33399119-787D3E1A-6751-4B63-95CA-3BCDDF736D5FQ33399580-E576FC3C-4352-4088-8B0A-BAEAEEB32923Q33400008-A689887B-7F18-4EC3-919F-A3F0A0A31DBFQ33400181-2AE72EDA-3788-459E-8FE3-5682CEF6FF5FQ33401236-2967A39A-9D6F-43D9-A386-F61FEA4F36F0Q33401466-D2B32475-ED22-403A-A2D9-80A53B341856Q33403113-9E99B3C0-9ED5-42B8-B4C0-9386008D9ACFQ33403437-BF84250B-4C34-4918-9076-5DE501586860Q33405248-F2B645E1-087A-40B8-A163-897368D11CFBQ33406245-A466DE80-FA36-4190-A042-009EEDA0A80EQ33406804-EBD77AD8-41D6-4916-8207-8B9B56B8F9B9Q33406904-530C6DAE-9667-490D-8F84-6CD5F893F048Q33407497-D6072FED-D077-4E91-A2D7-3FAB88544B2DQ33408778-7E3184F6-B0D9-4C0F-9D4E-07512B3B6DC5Q33409277-6AB9A7A9-4054-45A7-AC01-17C911AA3FEEQ33410017-B63EE2AB-06E3-4358-8E8A-51A56085081CQ33410801-46A73F8F-2D51-484A-88E9-CECFDCEF14BFQ33412220-23D77D26-8839-4A70-AB14-C1A62027CCA0Q33416315-C66D0F96-DB9F-4780-A0ED-AB72A9BBB810Q33416580-92CD6246-C81F-495E-96DF-B3DB72B953B2Q33418247-2496729E-145E-4015-91F0-73D3319277C4Q33418625-00FC618F-5511-4460-8C95-C51267DA81D2Q33418994-37B4233C-6A20-410A-8949-4F9A8644FD9A
P2860
Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Heparin-induced thrombocytopen ...... the IgG, IgM, and IgA classes.
@ast
Heparin-induced thrombocytopen ...... the IgG, IgM, and IgA classes.
@en
type
label
Heparin-induced thrombocytopen ...... the IgG, IgM, and IgA classes.
@ast
Heparin-induced thrombocytopen ...... the IgG, IgM, and IgA classes.
@en
prefLabel
Heparin-induced thrombocytopen ...... the IgG, IgM, and IgA classes.
@ast
Heparin-induced thrombocytopen ...... the IgG, IgM, and IgA classes.
@en
P2093
P2860
P1476
Heparin-induced thrombocytopen ...... the IgG, IgM, and IgA classes.
@en
P2093
Greinacher A
P2860
P304
P356
10.1111/J.1538-7836.2007.02617.X
P577
2007-05-07T00:00:00Z